Abstract:Background: Here we carried out a panoramic analysis of the expression and prognosis of HSP110, HSP90, HSP70, and HSP60 families in 33 types of cancer, with the aim of deepening the systematic understanding of heat shock proteins (HSPs) in cancer. Materials and Methods: Next-generation sequencing data of multiple tumors were downloaded from TCGA, CCLE and Oncomine databases. RStudio 3.6.1 was used to analyze HSP110, HSP90, HSP70 and HSP60 families based on their expression in 33 types of cancer. The validations in vivo (stomach adenocarcinoma and colon adenocarcinoma tissues) were performed by qRT-PCR. Results: HSPs were differentially expressed in different cancers. The results revealed mainly positive correlations among the expressions of HSPs in different cancers. Expressions of HSP family members were generally associated with poor prognosis in respiratory, digestive, urinary and reproductive system tumors and associated with good prognosis in cholangiocarcinoma, pheochromocytoma and paraganglioma. TCGA mutation analysis showed that HSP gene mutation rate in cancers was 0–23%. CCLE mutation analysis indicated that HSP gene mutation rate in 828 cell lines from 15 tumors was 0–17%. CNV analysis revealed that HSPs have different degrees of gene amplifications and deletions in cancers. Gene mutations of 15 HSPs influenced their protein expressions in different cancers. Copy number amplifications and deletions of 22 HSPs also impacted protein expression levels in pan-cancer. HSP gene mutation was generally a poor prognosis factor in cancers, except for uterine corpus endometrial carcinoma. CNVs in 14 HSPs showed varying influences on survival status in different cancers. HSPs may be involved in the activation and inhibition of multiple cancer-related pathways. HSP expressions were closely correlated with 22 immune cell infiltrations in different cancers. The qRT-PCR validation results in vivo showed that HSPA2 was down-regulated in stomach adenocarcinoma and colon adenocarcinoma; HSPA7 and HSPA1A also were down-regulated in colon adenocarcinoma. HSPA2-HSPA7 (r = 0.031, p = 0.009) and HSPA1A-HSPA7 (r = 0.516, p < 0.001) were positive correlation in colon adenocarcinoma. Conclusion: These analysis and validation results show that HSP families play an important role in the occurrence and development of various tumors and are potential tumor diagnostic and prognostic biomarkers as well as anti-cancer therapeutic targets.

The multiple roles and therapeutic potential of HSP60 in cancer

The multifunction of HSP70 in cancer: Guardian or traitor to the survival of tumor cells and the next potential therapeutic target

HSP70 Family in Cancer: Signaling Mechanisms and Therapeutic Advances

HSP70 Multi-Functionality in Cancer

Hsp60 Exerts a Tumor Suppressor Function by Inducing Cell Differentiation and Inhibiting Invasion in Hepatocellular Carcinoma

Comprehensive Pan-Cancer Analysis of Heat Shock Protein 110, 90, 70, and 60 Families

HSP70 and HSP90 in Cancer: Cytosolic, Endoplasmic Reticulum and Mitochondrial Chaperones of Tumorigenesis

Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance

The Multiple Roles and Therapeutic Potential of Molecular Chaperones in Prostate Cancer

Hsp70 in cancer: A double agent in the battle between survival and death

HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)

New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potential

HSP60-regulated Mitochondrial Proteostasis and Protein Translation Promote Tumor Growth of Ovarian Cancer

Current Understanding and Future Prospects

Toward Developing Chemical Modulators of Hsp60 as Potential Therapeutics

Mechanisms of Action of HSP110 and Its Cognate Family Members in Carcinogenesis

Clinicopathologic significance of heat shock protein 60 as a survival predictor in breast carcinoma

Roles of heat shock proteins in tumor immune microenvironment

The 60‐kda Heat Shock Protein Regulates Energy Rearrangement and Protein Synthesis to Promote Proliferation of Multiple Myeloma Cells

Progress of study on Hsp90 inhibitors